https://www.selleckchem.com/products/ap20187.html
Long-term data on patients over 75 years undergoing mitral valve (MV) repair are scarce. At our high-volume institution, we, therefore, aimed to evaluate mortality, stroke risk, and reoperation rates in these patients. We investigated clinical outcomes in 372 patients undergoing MV repair with ( = 115) or without ( = 257) tricuspid valve repair. The primary endpoint was the probability of survival up to a maximum follow-up of 9 years. Secondary clinical endpoints were stroke and reoperation of the MV during follow-up. Univariate and
Like
Comment
Share
